Gilead Sciences (GILD) shares oversold argues BofA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St set for higher open as AI stocks rise, oil slides
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Streamflation drives 39% of Americans to cancel streaming in 6 months
- Wall St set for higher open as AI stocks rise, oil slides
BofA Securities Upgrades Gilead Sciences (GILD) to Buy on HIV drug upside
September 8, 2023 6:05 AM EDT(Updated - September 8, 2023 6:40 AM EDT)
BofA Securities analyst Geoff Meacham upgraded Gilead Sciences (NASDAQ: GILD) from Neutral to Buy with a price target of $95.00 (from $88.00).
The analyst commented "We are upgrading GILD shares to Buy (from Neutral) and raising our PO to... More
Gilead Sciences (GILD) Prices $2B Notes Offering
September 8, 2023 5:46 AM EDTGilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, today announced the pricing of senior unsecured notes in an aggregate principal amount of $2 billion, in an underwritten, registered public offering, consisting of $1... More
Amgen and Biogen 'look attractive' - HSBC
September 6, 2023 11:39 AM EDTHSBC initiated coverage of 11 US biopharmaceutical and healthcare stocks in a note to clients on Wednesday.
Analyst Morten Herholdt assigned Actinium Pharma (NYSE: ATNM), Amgen (NASDAQ: AMGN), Biogen (NASDAQ: BIIB), Bluebird... More
HSBC Starts Gilead Sciences (GILD) at Reduce
September 6, 2023 3:14 AM EDTHSBC analyst Morten Herholdt initiates coverage on Gilead Sciences (NASDAQ: GILD) with a Reduce rating and a price target of $71.00.
For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.
Shares of Gilead Sciences closed at $75.16 yesterday.
... More